Structure Therapeutics (GPCR) vs Trevi Therapeutics (TRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Trevi Therapeutics (TRVI) has outperformed Structure Therapeutics (GPCR) over the past year, gaining 30.6% versus a loss of 9.8%. Structure Therapeutics is the larger company by market cap ($1.83 billion vs $1.83 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GPCR | TRVI |
|---|---|---|
| Share price | $25.67 | $12.83 |
| Market cap | $1.83B | $1.83B |
| 1-day change | -3.79% | -2.40% |
| YTD return | -63.09% | +2.44% |
| 1-year return | -9.77% | +30.60% |
| 5-year return | — | +894.19% |
| EPS (TTM) | $-2.91 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $94.90 | $20.22 |
| 52-week low | $25.09 | $9.28 |
| Distance from 52-week high | -72.95% | -36.57% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +312.08% | +119.73% |
| Average volume | 965.00K | 1.95M |
| Shares outstanding | 71.31M | 142.48M |
| Employees | 281 | 34 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRVI has outperformed GPCR by 40.4 percentage points over the past year.
- The two companies sit in different sectors: Structure Therapeutics in Healthcare and Trevi Therapeutics in Health Care.
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Healthcare · Biotechnology · 281 employees
About Trevi Therapeutics
TRVI stock →Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
GPCR vs TRVI FAQ
Which is bigger, Structure Therapeutics or Trevi Therapeutics?
Structure Therapeutics (GPCR) is larger, with a market capitalization of $1.83B compared with $1.83B for Trevi Therapeutics (TRVI).
Which stock has performed better over the past year, GPCR or TRVI?
TRVI returned +30.60% over the past 12 months, compared with -9.77% for GPCR (price return, excluding dividends). Past performance does not predict future results.
Are Structure Therapeutics and Trevi Therapeutics in the same industry?
No. Structure Therapeutics is in the Healthcare sector, while Trevi Therapeutics is in Health Care.